Results - Announcements
ERIS Lifesciences Ltd share price softened by 2.14% to Rs 1097.65. The Company's net profit surged by 30.57% to Rs 187.14 crore, while revenue from operations slightly gained 2.36% to Rs 889.5 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.19 lakh crore, easing 3.50%. It has eased by 1.73% over last one week and softened by 3.54% in last one month while the market capitalization of ERIS Lifesciences Ltd has slipped by 2.49% and 21.02% in the same period respectively.
Profit before tax (PBT) of ERIS Lifesciences Ltd stood at Rs 155.91 crore in Q3 FY26, declining 9.71% year-on-year, and retreating 13.14% quarter-on-quarter. EBITDA came in at Rs 306 crore, rising 7.27% YoY and gaining 4.19% sequentially.
Total expenses inched up 1.13% to Rs 656.44 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 107.86 crore, increasing 14.42% YoY, while employee benefits expense was at Rs 149.19 crore, softening 2.76% YoY.
For the TTM ended FY26, revenue from operations posted a slight growth of 8.18% to Rs 3114.89 crore, while net profit soared by 72.82% to Rs 647.51 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 96188% to Rs 1112.36 crore, and PBT soared 30.62% to Rs 638.54 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 537.99 crore in FY26, as against Rs 1065.01 crore in FY25.
ERIS Lifesciences Ltd crashed 30.95% in last one year, underperforming the benchmark BSE Sensex which has reduced by 13.52% during the same period.